Prosecution Insights
Last updated: November 10, 2026
Application No. 19/067,759

NOVEL METHOD TO ALTER THE PROTEOME OF A DISEASED HEART BY INJECTION OF ECM PARTICLES PRODUCED FROM DECELLULARIZED 3D MICROTISSUES OF HUMAN MESENCHYMAL STEM CELLS

Final Rejection §102§103
Filed
Feb 28, 2025
Priority
Dec 23, 2020 — provisional 63/129,966 +4 more
Examiner
AFREMOVA, VERA
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Xm Therapeutics Inc.
OA Round
2 (Final)
51%
Grant Probability
Moderate
3-4
OA Rounds
1y 11m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
449 granted / 888 resolved
-9.4% vs TC avg
Strong +29% interview lift
Without
With
+29.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
48 currently pending
Career history
959
Total Applications
across all art units

Statute-Specific Performance

§101
8.0%
-32.0% vs TC avg
§103
45.9%
+5.9% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 888 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of claims Claims 1-5, 7-11 and 13-20 as amended on 9/23/2026 are currently pending. Claims 13-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/01/2056. Claims 1-5 and 7-11 as amended on 9/23/2026 are under examination in the instant office action. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-5 and 7-11 as amended are now rejected under 35 U.S.C. 103 as being unpatentable over Assuncao et al (“Cell-derived extracellular matrix for tissue engineering and regenerative medicine”. Frontiers in Bioengineering and Biotechnology. Published 03 December 2020. Volume 8, article 602009, pages 1-10) in view of Wai Hoe Ng et al (“Extracellular matrix from decellularized mesenchymal stem cells improves cardiac gene expression and oxidative resistance of cardiac C-kit cells”. Regenerative Therapy, 2019, 11, pages 8-16) and Geon Hiu Lee et al (Adv Health Mater, 2016, (1), 56-74). The cited reference by Assuncao teaches that cell-derived extra-cellular matrices (CD-ECM) are increasingly used in therapeutic applications (see abstract) including treating and repairing cardiovascular tissues (page 6) including diseased heart (figure 2). The cell-derived ECM are decellularized to remove immunogenic components (see page 2, col. 1, par. 3, line 5; see page 2, col. 2, par. 4-5). The cell-derived ECM are produced by several methodologies including 3D cultures of spheroids or 3D microtissues (figure 1). The cited reference by Assuncao recognizes that culturing ECM-secreting cells in 3D format achieves mechano-physical re-engineering of ECM scaffolds with unique architecture (page 5, col. 1, par. 4). ). The cited reference by Assuncao acknowledges that application of cell-derived ECM improves cardiac remodeling (Page 6, par. 3). The cited reference by Assuncao also recognizes the use of mesenchymal stem cells (MSC) - derived ECM for recapitulation of stem cell niche sufficiently, for protection of cells from oxidative stress and for promoting cell proliferation and cell differentiation (page 3, col. 2, lines 1-3) in therapeutic applications for tissue repairs. Thus, as a whole, the cited reference by Assuncao teaches and suggests a method of treating a diseased heart and improving cardiac function by contacting the diseased heart with the cell derived ECM (figure 2), wherein the cell-derived ECM is made from 3D microtissues (fig. 1) by decellularization to remove immunogenicity . Although the cited reference by Assuncao recognizes the beneficial effects of mesenchymal stem cells (MSC) - derived ECM for recapitulation of stem cell niches, the disclosure is silent about direct effects of ECM of decellularized MSC on cardiac cell function. However, the prior art clearly teaches that ECM of decellularized MSC improves cardiac gene expression and oxidative resistance of cardiac cells, thereby, altering proteome of disease heart. For example: see the reference by Wai Hoe Ng (entire document including abstract). The cardiac beneficial ECM was obtained from of decellularized MSC cultured in vitro in 2D environment as disclosed by the cited reference (see section 2.4). But Geon Hiu Lee teaches that 3D microtissues could be made from MSC (table 1) and that 3D microtissues made from MSC maintain their multipotency and enhanced differentiation compared with 2D monolayers (page 58, col. 1, lines 10-12 from bottom). Therefore, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was filed to use ECM derived from cultured and decellularized MSC in a method for cardiac remodeling and/or treating a diseased heart as taught and suggested by Assuncao with a reasonable expectation of success because ECM of cultured and decellularized MSC improves cardiac gene expression and oxidative resistance of cardiac cells, thereby, altering proteome of disease heart, as taught by Wai Hoe Ng. The use of ECM of decellularized MSC obtained either 2D culture (Wai Hoe Ng) or by 3D culture (Geon Hiu Lee) is considered to be a substitution of equivalents because both environments provide for biologically active ECM of MSC. Thus, the claimed invention as a whole was clearly prima facie obvious, especially in the absence of evidence to the contrary. The claimed subject matter fails to patentably distinguish over the state art as represented be the cited references. Therefore, the claims are properly rejected under 35 USC § 103. Response to Arguments Applicant's arguments filed on 9/23/2026 have been fully considered but they are not all found persuasive. The rejection of claims under 35 U.S.C. 102 (a) (1) as being anticipated by Ravi et al (“Effect of bone marrow-derived extracellular matrix on cardiac function after ischemic injury”. Biomaterials. November 2012, 33 (1), pages 1-13) has been withdrawn in view of current claim amendment and applicants’ arguments that the cited reference does not teach the use of ECM derived from cultured 3D microtissues derived from human mesenchymal stem cells for treating a diseased heart. With regard to claim rejection under 35 USC § 103 Applicant’s arguments with respect to claims as amended have been considered but are moot because the new ground of rejection necessitated by claim amendment. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA AFREMOVA whose telephone number is (571)272-0914. The examiner can normally be reached Monday-Friday: 8.30am-5pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached at (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Vera Afremova October 23, 2026 /VERA AFREMOVA/ Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Feb 28, 2025
Application Filed
Mar 23, 2026
Non-Final Rejection mailed — §102, §103
Sep 23, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779001
APPLICATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARATION OF DRUGS FOR TREATING NEURITIS
2y 5m to grant Granted Nov 03, 2026
Patent 12766172
COMPOSITION FOR PREVENTING, TREATING, OR IMPROVING GASTROINTESTINAL DISEASES COMPRISING STRAIN OF GENUS CORYNEBACTERIUM AND CULTURE THEREOF
4y 10m to grant Granted Oct 20, 2026
Patent 12747444
Heterotrophic Production Methods for Microbial Biomass and Bioproducts
5y 6m to grant Granted Sep 29, 2026
Patent 12721871
PROBIOTICS FOR THE PREVENTION OR TREATMENT OF VIRAL RESPIRATORY INFECTIONS
1y 10m to grant Granted Sep 01, 2026
Patent 12708650
Recombinant Bacteria And Uses Thereof
4y 11m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
51%
Grant Probability
80%
With Interview (+29.4%)
3y 7m (~1y 11m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 888 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month